Company intelligence / Profile preview

AzERx

Chandler, Arizona, USA

Ownership: Private
Development stage: Other

Overview

AzERx (Arizona Engineered Therapeutics) was a biotechnology company focused on the development of peptide-based therapeutics for smooth muscle relaxation and fibrosis prevention. Spun out of Arizona State University, the company's core technology centered on synthetic analogs of heat shock protein 20 (HSP20). Its lead candidate, AZX100, was developed to treat conditions such as keloid and hypertrophic scarring, pulmonary fibrosis, and asthma. AzERx was acquired by OrthoLogic Corp. (now Capstone Therapeutics) in 2006 for approximately $8 million.

Therapeutic areas: CardiovascularPulmonologyDermatology
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on AzERx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AzERx.

Explore the full profile